Voloridge Investment Management
ENTA icon

Voloridge Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Voloridge Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,140
Closed -$579K – 1484
2022
Q1 		$579K Sell
8,140
-37,343
-82% -$2.43M ﹤0.01% 1204
2021
Q4 		$3.4M Buy
45,483
+33,319
+274% +$2.61M 0.02% 867
2021
Q3 		$691K Buy
+12,164
New +$601K ﹤0.01% 1382
2021
Q1 		– Sell
-50,052
Closed -$2.11M – 1465
2020
Q4 		$2.11M Buy
50,052
+799
+2% +$35.2K 0.02% 719
2020
Q3 		$2.25M Buy
49,253
+19,330
+65% +$937K 0.02% 679
2020
Q2 		$1.5M Sell
29,923
-24,560
-45% -$1.27M 0.02% 712
2020
Q1 		$2.8M Buy
54,483
+17,707
+48% +$944K 0.08% 270
2019
Q4 		$2.27M Buy
36,776
+24,808
+207% +$1.54M 0.04% 459
2019
Q3 		$719K Buy
+11,968
New +$889K 0.01% 716
2019
Q2 		– Sell
-11,288
Closed -$1.08M – 836
2019
Q1 		$1.08M Sell
11,288
-4,383
-28% -$393K 0.03% 447
2018
Q4 		$1.11M Buy
+15,671
New +$1.2M 0.05% 260

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Voloridge Investment Management's ENTA Position: Q2 2022 in Review

Voloridge Investment Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2022, closing a stake of 8,140 shares — an estimated $579K sold.

Voloridge Investment Management first reported a position in ENTA in Q4 2018 and held it in 11 quarters. The position peaked at $3.4M in Q4 2021. 154 funds tracked by Wall St. Rank hold ENTA as of Q2 2022.

  • Voloridge Investment Management reported no remaining Enanta Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Voloridge Investment Management sold 8,140 Enanta Pharmaceuticals shares in Q2 2022, an estimated $579K.
  • Voloridge Investment Management first reported a position in Enanta Pharmaceuticals in Q4 2018 and held it in 11 quarters.
  • Voloridge Investment Management's Enanta Pharmaceuticals position peaked at $3.4M in Q4 2021.
  • 154 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2022.

Based on Voloridge Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.